Shares of Illumina (ILMN) were lower Tuesday after the biotech firm cut its third-quarter sales expectations to $607 million, that's down more than 3% from the midpoint of its prior guidance. Illumina also said it expects to see a fall in sales of its sequencing instruments. Analysts with Cantor Fitzgerald wrote Tuesday that Illumina's troubles are "largely company-specific" and that Cantor Fitzgerald is still positive on industry peers such as Pacific Biosciences (PACB) .
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.